1. Market Research
  2. >Pharmaceutical
  3. >Therapy Market Trends
C-X-C趋化因子受体2型-管道审查, H2 2019

C-X-C趋化因子受体2型-管道审查, H2 2019

  • November 2019
  • 69 pages
  • ID: 5830785
  • Format: PDF
  • By Global Markets Direct

Summary

Table of Contents

Search Inside

C-X-C趋化因子受体2型-管道审查, H2 2019

Summary
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 17 molecules.Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor.It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system.This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth.This receptor mediates neutrophil migration to sites of inflammation.The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor.The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 1, 6 and 1 respectively.Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Respiratory, Cardiovascular, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Breast Cancer, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects.Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
——报告评论C-X-C趋化因子受体类型 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get Industry Insights.Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • 单用户许可— provides access to the report by one individual.
  • 部门许可— allows you to share the report with up to 5 users
  • 站点许可证- 允许该报告向所有员工之间在规定的国家共享
  • 法人许可证- 允许完全访问权限,在全球范围。
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided.The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product.He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service.Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry.The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations.I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks!I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • 我不知道我是否有兴趣在该报告将满足我的需求。你能帮助我吗?
    • 当然是。您可以在+33(0)37 4 65 17 03给我们打电话或发邮件到电子邮件researchadvisor@威廉竞彩appreportlinker.com让我们更多地了解您的需求。
    • 我们经常买报告 - 可以ReportLinker让我什威廉竞彩app么好处?
    • 是。建立呼叫与高级研究顾问,以了解更多 -researchadvisor@威廉竞彩appreportlinker.com或+33(0)4 37 65 17 03。
    • 我曾与之前的市场调查报告,负面的经验。你怎么能再次避免这种情况发生?
    • 我们建议所有客户端读取TOC和摘要,并列出您的问题,这样我们可以得到您更多的了解你做出任何购买决定之前。一个研究顾问会陪你,让你可以比较来自不同来源的样品和报告,并选择研究,是适合你的。

  • Report Delivery
    • 如何及何时我能收到我的报告?
    • 大多数报告都以pdf格式马上交付,而另一些则通过安全链接和访问代码访问。做笔记,有时报告12小时内发出,这取决于时区。但是,您可以与我们联系,以上报。如果你需要一个硬拷贝,你可以检查此选项供的特定报表,并支付相关费用。
  • Payment conditions
    • 你接受什么支付方式?
      1. 信用卡:VISA,美国运通,万事达,或
      2. 您可以通过电汇从公司下载发票,支票,或通过采购订单,或
      3. 您可以通过在美元,欧元或英镑做出来的全额支票支付支付给ReportLinker威廉竞彩app
    • 什么是Report威廉竞彩appLinker的付款方式?
    • 所有款项通常必须在30天内提交。但是,您可以让我们知道,如果你需要更长的时间。
    • 是税收和关税包括在内?
    • 总部设在法国的所有公司必须支付每报表中的20%的税。这同样适用于总部设在欧盟的所有个体。所有的欧盟企业采购时避免这项收费必须提供其增值税号码。
    • 我不满意。我可以退还?
    • 没有。一旦您的订单已被处理,发布已收到一个通知,发送给您的报告中,我们不能发出任何退款或取消任何订单。由于这些都不是可以退换的“传统”的产品,分派的报告被认为是“消费”。
  • User license
    • 你应该获得许可证取决于人需要访问该报告的数量。从单用户这可以范围(只有一个人都会有阅读权或访问报告),或部门许可(最多5人),到站点许可证(基于在同一个公司的位置的一组人士),或公司 License (the entire company personnel based worldwide).然而,出版商有不同的条款和条件,我们可以看看这个给你。
Purchase Reports From Reputable Market Research Publishers
C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019

C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019SummaryC-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) pipeline Target ...

Aplastic Anemia Global Clinical Trials Review, H2, 2019

Aplastic Anemia Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Aplastic Anemia Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Aplastic Anemia Global Clinical Trials Review, H2, 2019" provides an overview of Aplastic Anemia clinical trials ...

碳碳趋化因子受体类型5 -管道审查,H2 2019

碳碳趋化因子受体类型5 -管道审查,H2 2019

  • $ 3500
  • November 2019

碳碳趋化因子受体类型5 -管道审查,H2 2019SummaryAccording to the recently published report ’C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019’;C-C Chemokine Receptor Type 5 (CHEMR13 ...


ref:plp2019

Reportlinker.com © Copyright 2020.All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on